A study led by the group of Didier Trono at EPFL has revealed a crucial survival tactic employed by cancer cells. The scientists have identified a group of proteins, known as "KRAB zinc finger proteins" (KZFPs), that help ...
Feb 12, 2024
0
0
Researchers with McMaster University and Denmark-based pharmaceutical company ALK-Abello A/S have made a groundbreaking discovery: a new cell that remembers allergies.
Feb 7, 2024
0
216
As new cancer treatments become available, some of the most important ongoing research must look at ways to optimize those new approaches so that more patients can benefit from groundbreaking therapies. In work published ...
Feb 5, 2024
0
0
Nearly four years into the pandemic, Australia, like many other countries, is still seeing large numbers of COVID cases. Some 860,221 infections were recorded around the country in 2023, while 30,283 cases have already been ...
Jan 23, 2024
0
0
Researchers with McMaster University have created an instruction manual that will help scientists across the globe find hard to detect B cells.
Jan 19, 2024
0
45
After COVID vaccination, it usually takes weeks for our bodies to develop protective antibody responses. Imagine, however, a vaccine that speeds up the production of antibodies against SARS-CoV-2, the virus that spreads COVID-19.
Jan 17, 2024
0
36
An innovative computational tool dubbed "SNAF" may help the research world bring the emerging promise of cancer immunotherapy to a wider range of patients, according to a study published in Science Translational Medicine. ...
Jan 17, 2024
0
42
Chimeric antigen receptor T-cell therapy, or CAR T, has dramatically improved the treatment of certain blood cancers. Initially approved for patients who had failed multiple lines of therapy, clinical trials have shown CAR ...
Jan 17, 2024
0
36
A new study sheds light on how autophagy, the body's process for removing damaged cell parts, when impaired, can play a role in causing heart failure.
Jan 11, 2024
0
2
Lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T-cell therapy, is cost-effective for second-line diffuse large B-cell lymphoma (DLBCL) therapy, according to a study published online Dec. 28 in Blood ...
Jan 4, 2024
0
0
